Results 181 to 190 of about 555,285 (355)

A Systemic Selective Modified mRNA Delivery Platform for Preventing Chemotherapy‐Induced Cardiotoxicity

open access: yesAdvanced Science, EarlyView.
In Yoo and Mainkar et al., we present a minimally invasive, CM‐selective modRNA delivery system encapsulated in lipid nanoparticles for intravenous (IV) administration. This platform enables selective cardiac translation of therapeutic modRNA but suppresses expression in off‐target tissues, including tumors.
Jimeen Yoo   +19 more
wiley   +1 more source

PARPi Combining Nanoparticle LIN28B siRNA for the Management of Malignant Ascites

open access: yesAdvanced Science, EarlyView.
This study demonstrates that co‐inhibition of LIN28B and PARP using siLin28b/DSSP@lip‐PEG‐FA nanoparticles in combination with the PARP inhibitor BMN673 effectively suppresses the accumulation of malignant ascites associated with advanced cancers.
Yan Fang   +13 more
wiley   +1 more source

Temporal Transcriptional Regulation of Human Neuronal Differentiation via Forward Programming

open access: yesAdvanced Science, EarlyView.
Single‐cell profiling of TF‐induced forward programming versus stepwise dual‐SMAD differentiation reveals that divergent trajectories set the pace of neurogenesis. OLIG TFs advance cell‐cycle exit via NOTCH modulation, while NEUROD2 later accelerates maturation. The study elucidates transcriptional mechanisms governing differentiation timing, providing
Lingling Zhu   +13 more
wiley   +1 more source

Promoting Autophagy Mitigates Stress‐Induced Remodeling in Patient iPSC‐CMs with the Phospholamban R9C Mutation

open access: yesAdvanced Science, EarlyView.
The Phospholamban (PLN) R9C mutation reduces SERCA2a binding, increasing calcium recycling and baseline contractility. However, the excess of free PLN promotes pentamer formation, limiting phosphorylation and blunting β‐adrenergic signaling. Under cardiac stress, enhanced functional demands overwhelm proteostasis in PLN R9C cells, leading to misfolded ...
Qi Yu   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy